Chiral stability-indicating HPLC method for analysis of arotinolol in pharmaceutical formulation and human plasma

Arabian Journal of Chemistry

Volumn 3, Issue 3, 2010, Pages 147-153

  Sultan, Maha A ^a   Hefnawy, Mohamed M ^a   Al Shehri, Mona M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Arotinolol; Chiral separation; Chirobiotic V; Degradation study; Human plasma; Pharmaceutical formulation

Indexed keywords

CHIRAL SEPARATIONS; DEGRADATION PRODUCTS; DEGRADATION STUDY; DETECTION LIMITS; ENANTIOSELECTIVE; ETHYL ETHER; EXTRACTION EFFICIENCIES; GLACIAL ACETIC ACID; HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHODS; HPLC METHOD; HUMAN PLASMAS; INTERNATIONAL CONFERENCE ON HARMONIZATIONS; LIQUID-LIQUID EXTRACTION PROCEDURE; MOBILE PHASE; OXIDATIVE CONDITIONS; PHARMACEUTICAL FORMULATION; RELATIVE STANDARD DEVIATIONS; REPRODUCIBILITIES; STANDARD SOLUTIONS; STOCK SOLUTIONS; STRESS CONDITION; TRIETHYLAMINES; UV DETECTOR;

CHIRALITY; CHROMATOGRAPHIC ANALYSIS; ENANTIOMERS; ETHERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUIDS; METHANOL; PHOTODEGRADATION; PHOTOLYSIS; PLASMA (HUMAN); PLASMA STABILITY; PLASMAS; SOLVENT EXTRACTION;

DRUG PRODUCTS;

EID: 77955581895     PISSN: 18785352     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arabjc.2010.04.002     Document Type: Article

References (21)

1. Aboul-Enein H.Y., Ali I. Chromatographia 2000, 52:679.
2. Aboul-Enein H.Y., Ali I. Il Farmaco 2002, 57:513.
3. Aboul-Enein H.Y., Hefnawy M.M. Biomed. Chromatogr. 2003, 17:453.
4. Ahuja S. Impurities Evaluation of Pharmaceuticals 1998, Marcel Dekker, Inc., New York, USA.
5. Ahuja S., Alsante K.M. Handbook of Isolation and Characterisation of Impurities in Pharmaceuticals 2003, Academic Press, San Diego, USA.
6. Baaske D.M., Demay J.F., Latona C.A., Mirmira S., Sigvardson K.W. Am. J. Health-Syst. Pharm. 1996, 53:1701.
7. Chirobiotic Handbook, 2004. Advanced Separation Technology, fifth ed. Whipppany, New York.
8. Daraghmeh N., Al-Omari M., Badwan A.A., Jaber A.M. J. Pharm. Biomed. Anal. 2001, 25:483.
9. Duret Ph., Foucault A., Margraff R. J. Liq. Chromatogr. Relat. Technol. 2000, 23:295.
10. Ekborg-Ott K.H., Liu Y., Armstrong D.W. Chirality 1998, 10:434.
11. FDA, 1998. Guidance for Industry: Impurities in Drug Product, Draft Guidance. Center for Drug Evaluation and Research (CDER).
12. Fried K.M., Koch P., Wainer I.W. Chirality 1998, 10:484.
13. Hefnawy M.M. Chirality 2002, 14:67.
14. ICH, 2003. Stability testing of new drug substances and products Q1A (R2). In: International Conference on Harmonization. IFPMA, Geneva.
15. Imai Y., Watanabe N., Hashimoto J., Sakuma H., Omata K., Abe K. Eur. J. Clin. Pharmacol. 1995, 48:29.
16. Moulin A., Truer D., Maillet E., Dufour A. J. Liq. Chromatogr. 1992, 15:151.
17. Pettersson C., Persson B. Handbook of HPLC 1998, 669. Marcel Dekker, New York. E. Katz, R. Eksteen, P. Schoenmakers, N. Miller (Eds.).
18. Subramanian G. A Practical Approach to Chiral Separations by Liquid Chromatography 1994, VCH, Verlagsgesellschaft mbH, Weinheim, Germany. G. Subramanian (Ed.).
19. The United States Pharmacopeia, 2000. United States Pharmacopeial Convention, 24th ed. Rockville, MD, p. 2150.
20. Török G., Goetelen L., Luyckx R., Broeck P.V. J. Pharm. Biomed. Anal. 2005, 39:425.
21. Van-Zwieten P.A. Drugs 1993, 45:509.